Bluejay Diagnostics, Inc.

AI-generated fair value estimate for this company.

Method: Net cash-based valuation: $9.52M net cash divided by 4.47M shares equals $2.13/share cash value, discounted roughly 15% to $1.80/share to reflect ongoing operating burn (approximately $5.9M per year of operating cash outflow) and dilution risk from likely future capital raises before the Symphony diagnostic platform reaches meaningful commercial revenue.

Reasoning: Bluejay is pre-commercial with no meaningful revenue, so intrinsic value is best anchored to its net cash position (which already exceeds the market price) rather than a cash-flow DCF; the discount to full cash value accounts for continued cash burn and financing/dilution risk before commercialization.